Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14116880 | 0.98 | KMT2A (0.60) | KMT2AMEN1KDM4EPOLBATM | |
| SCHEMBL67311 | 0.98 | KMT2A (0.60) | KMT2AMEN1KDM4EPOLBATM | |
| SCHEMBL20027940 | 0.98 | KMT2A (0.60) | KMT2AMEN1KDM4EPOLBATM | |
| SCHEMBL14355276 | 0.94 | KMT2A (0.54) | KMT2AMEN1KDM4EPOLBATM | |
| SCHEMBL14116870 | 0.94 | KMT2A (0.54) | KMT2AMEN1KDM4EPOLBATM | |
| SCHEMBL9621208 | 0.89 | KDM4E (0.50) | KMT2AMEN1KDM4EPOLBATM | |
| SCHEMBL3969316 | 0.89 | KDM4E (0.50) | KMT2AMEN1KDM4EPOLBATM | |
| SCHEMBL8283447 | 0.82 | USP2 (0.58) | KMT2AMEN1POLBCYP2D6CYP2C19 | |
| SCHEMBL23706771 | 0.82 | ALDH1A1 (0.55) | KMT2AMEN1KDM4EPOLBMAPT | |
| SCHEMBL23657198 | 0.82 | KDM4E (0.62) | KMT2AMEN1KDM4EPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262589-A1 | AMINE COMPOSITION FOR CARBON DIOXIDE SEPARATION USE | TOSOH CORPORATION (JP) | 2025-08-21 | — | — | US | disclosed |
| EP-4494740-A1 | AMINE COMPOSITION FOR CARBON DIOXIDE SEPARATION USE | TOSOH CORPORATION (JP) | 2025-01-22 | — | — | EP | disclosed |
| CN-119095662-A | Amine composition for separating carbon dioxide | 东曹株式会社 | 2024-12-06 | — | — | CN | disclosed |
| CN-114901383-A | Composition for separating carbon dioxide and method for separating carbon dioxide | 东曹株式会社 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021153650-A1 | COMPOSITION FOR CARBON DIOXIDE SEPARATION AND METHOD FOR SEPARATING CARBON DIOXIDE | 東ソー株式会社 | 2021-08-05 | — | — | WO | disclosed |
| US-8946444-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8129426-B2 | Water-soluble artemisinin derivatives, their preparation methods, the pharmaceutical compositions and the use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2012-03-06 | — | — | US | disclosed |
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090298881-A1 | Water-Soluble Artemisinin Derivatives, Their Preparation Methods, the Pharmaceutical Compositions and the Use Thereof | JIANGSU ZUOYOU MEDICINE CO., LTD. (CN) | 2009-12-03 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | KMT2A 320/4885MEN1 1165/4885KDM4E 488/4885 |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | VEGFA, FLT4, KDR | KMT2A 3806/4885MEN1 4608/4885KDM4E 518/4885 |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | KMT2A 2557/4885MEN1 2796/4885KDM4E 2367/4885 |
| US-20090298881-A1 | Water-Soluble Artemisinin Derivatives, Their Preparation Methods, the Pharmaceutical Compositions and the Use Thereof | NFATC1, THPO, SQLE | KMT2A 4018/4885MEN1 2419/4885KDM4E 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.